Seres Therapeutics grants 50,000 stock options

Seres Therapeutics, Inc. reported that director and officer Richard N. Kender received a grant of stock options covering 50,000 shares of common stock at an exercise price of $9.13 per share.

Rhea-AI Filing Summary

Seres Therapeutics, Inc. reported that director and officer Richard N. Kender received a grant of stock options covering 50,000 shares of common stock at an exercise price of $9.13 per share. These options vest in 36 equal monthly installments beginning on March 2, 2026, and are scheduled to expire on March 3, 2036. Following this grant, Kender holds stock options for 50,000 shares directly.

Insider Trade Summary

Grant/Award: 50,000 shares

Grant/Award 1 txn

Insider Kender Richard N

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	50,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 50,000 contracts (Direct)

Footnotes (1)

1. F1. The option vests and becomes exercisable in 36 equal monthly installments following the March 2, 2026 vesting commencement date.

Key Figures

Options Granted: 50,000 shares Exercise Price: $9.13 per share Expiration Date: March 3, 2036 +2 more

5 metrics

Options Granted 50,000 shares Stock option grant to Richard N. Kender reported as of transaction date July 8, 2026

Exercise Price $9.13 per share Conversion or exercise price for the 50,000 stock options

Expiration Date March 3, 2036 Scheduled expiration date of the granted stock options

Vesting Period 36 months Options vest in 36 equal monthly installments after March 2, 2026

Post-transaction Option Holdings 50,000 shares Total stock option shares held directly by Richard N. Kender after the grant

Key Terms

Stock Option, exercise price, vesting commencement date

3 terms

Stock Option financial

"The option vests and becomes exercisable in 36 equal monthly installments"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"conversion_or_exercise_price: "9.1300""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting commencement date financial

"following the March 2, 2026 vesting commencement date"

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did insider Richard N. Kender receive in the latest Form 4 for MCRB?

Richard N. Kender received a stock option grant for 50,000 shares of Seres Therapeutics common stock, with an exercise price of $9.13 per share and expiration on March 3, 2036.

How do the 50,000 Seres Therapeutics (MCRB) options granted to Richard N. Kender vest?

The 50,000 stock options granted to Richard N. Kender vest in 36 equal monthly installments starting from the March 2, 2026 vesting commencement date, gradually becoming exercisable over three years.

What is the exercise price of the options reported in the Seres Therapeutics (MCRB) Form 4?

The options reported for Richard N. Kender have an exercise price of $9.13 per share. They relate to Seres Therapeutics common stock and represent a right to buy 50,000 shares at that price.

When do Richard N. Kender’s Seres Therapeutics (MCRB) options expire?

The reported stock options held by Richard N. Kender are scheduled to expire on March 3, 2036. Any unexercised portion after this date will no longer be exercisable under the grant terms.

How many Seres Therapeutics (MCRB) option shares does Richard N. Kender hold after this transaction?

After the grant, Richard N. Kender holds stock options for 50,000 shares of Seres Therapeutics common stock directly, as reflected in the Form 4’s post-transaction holdings figure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/10/2026 - 04:15 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kender Richard N

(Last) (First) (Middle)

C/O SERES THERAPEUTICS, INC.

101 CAMBRIDGE PARK DRIVE

(Street)

CAMBRIDGE MASSACHUSETTS 02140

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Seres Therapeutics, Inc. [ MCRB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$9.13	07/08/2026		A		50,000		(1)	03/03/2036	Common Stock	50,000	$0	50,000	D

Explanation of Responses:

1. The option vests and becomes exercisable in 36 equal monthly installments following the March 2, 2026 vesting commencement date.

Remarks:

Interim Chief Executive Officer

	/s/ Thomas J. DesRosier, Attorney-in-Fact for Richard N. Kender	07/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)